You are here:
Gavi’s two funding streams, innovative finance and direct contributions account for 31% and 69% respectively of the Vaccine Alliance’s overall funding portfolio.
Multi-year pledges and commitments are crucial to sustaining Gavi's ongoing programmes and its ability to fund new vaccines.
Public-private partnerships Corporations, private individuals & foundations play a vital role in meeting Gavi needs, accounting for 23% of 2000 to 2014 funding.
Cultivation of key public & private donor relationships, co-financing, shaping vaccine markets and mobilising civil society advocacy.
The weighted average price of pentavalent vaccine per dose has dropped from US$ 3.56 in 2003 to US$ 1.90 in 2014.
29 October 2015
World Health Organisation right to be wary about first malaria vaccine
06 October 2015
Make vaccine coverage a key UN health indicator
22 August 2015
Vaccinations Bring Hope, Bracelets Deliver Reminders
The New York Times
24 July 2015
Malaria vaccine: How good is good enough?
23 July 2015
Sudan's other crisis
03 July 2015
Investment in child health in world's poorest countries saves 34m lives
03 March 2015
Ebola vaccine research in Africa
02 October 2013
Laos becomes first South East Asian nation to introduce pneumococcal vaccine
04 May 2013
Sojo Stories: Immunizing 250 Million Children By 2015
27 March 2013
Seth Berkley on Immunization in Pakistan
Heartfile eForum Blog
Concerned about the misuse of Gavi resources? Report it now.
© Gavi 2015
modal window here